Arbutus Biopharma(ABUS) Stock Price Today

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Arbutus Biopharma Showcases Promising Hepatitis B Treatments at EASL Congress 2025
TipRanksApr 23 06:33 ET
Express News | Arbutus Biopharma To Present Key Hepatitis B Data, Including Late-Breaker, At EASL Congress 2025
BenzingaApr 23 02:29 ET
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025
Arbutus BiopharmaApr 23 00:00 ET
Arbutus Biopharma Down Over 8%, on Pace for Largest Percent Decrease Since April 2023 -- Data Talk
Dow JonesApr 7 11:20 ET
Arbutus Biopharma Faces Executive Changes Amid Legal Battle
TipRanksApr 3 16:30 ET
Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year?
Yahoo FinanceMar 31 09:40 ET

Comments

Clintzilla

Mar 17 01:48

$Arbutus Biopharma (ABUS.US)$ Institutions steal the whole float yet? blackrock only has 13mill shares, vanguard 9mill.. nothing to see here

Jaguar8

Nov 16, 2024 00:05

ADDED NEWS

$Arbutus Biopharma (ABUS.US)$
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
Arbutus Biopharma (ABUS) announced promising results from its IM-PROVE I Phase 2a clinical trial for imdusiran, its RNAi therapeutic for chronic hepatitis B virus (cHBV).
When combined with 24 weeks of pegylated interferon and nucleos(t)ide analogue therapy, the treatment achieved a 50% functional cure rate (3/6 patients) in patients with baseline ...

1

Jaguar8

Nov 16, 2024 00:02

NEWS

$Arbutus Biopharma (ABUS.US)$
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Arbutus Biopharma and Barinthus Bio announced new preliminary data from Phase 2a IM-PROVE II trial for chronic hepatitis B treatment.
The study evaluated the combination of imdusiran, VTP-300, and low-dose nivolumab.
Key findings show that 23% of participants receiving the triple combinati...

1

Jaguar8

Oct 15, 2024 20:58

NEWS

$Arbutus Biopharma (ABUS.US)$
Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
Arbutus Biopharma (Nasdaq: ABUS) announced that clinical data for imdusiran, an RNAi therapeutic for chronic hepatitis B virus (cHBV) infection, will be presented in four posters at the AASLD - The Liver Meeting® 2024. Two late-breaking posters will feature data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials.
Key findings fr...